Forecasting & Franchise Strategy
Strengthen your portfolio by making more informed decisions and prepare for the impact of new research discoveries.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSArticle
Alzheimer's Disease - A Burgeoning Market on the Horizon
IQVIA Pipeline Link/Trial Link
Aug 15, 2024
Alzheimer's disease is an irreversible progressive neurodegenerative disease characterized by the misfolding of the amyloid beta protein, which accumulates to form toxic amyloid plaques and protein tau in the brain that impairs cognitive function and leads to premature death.
Alzheimer's manifests mainly in individuals aged 65 years and older and is the most common form of dementia. The disease progresses in three stages: the preclinical stage without symptoms; the prodromal stage with mild cognitive impairment and the dementia stage with functional impairment.1 The World Health Organization has estimated that Alzheimer's and other dementias affect more than 55 million people worldwide and impose a global annual economic burden of USD 1.3 trillion in associated healthcare costs.
Treatment options for Alzheimer's disease
There are currently no drugs that cure, prevent or reverse the course of Alzheimer's disease and available treatments provide symptomatic relief of symptoms such as memory loss for a limited time. The two main classes of therapeutics include cholinesterase inhibitors, which prevent the breakdown of the neurotransmitter acetylcholine, and N-methylD-aspartate receptor antagonists that regulate the activity of glutamate excitotoxiity.
Biogen won the race to get the first of a new category of medication to market for Alzheimer's disease with the accelerated approval of aducanumab (ADUHELM), a humanized monoclonal antibody that targets amyloid beta, in the USA in June 2021. However, many healthcare providers and insurers have refused to cover aducanumab due to a lack of clear clinical benefit. In January 2024, Biogen announced it will discontinue the development and commercialization of aducanumab to reprioritize resources to advance new treatment modalities in this therapeutic area. Patients who are receiving aducanumab as part of a clinical trial and by prescription will have access to the drug until May 2024 and Nov 2024, respectively.
The accelerated approval of Eisai and Biogen's lecanemab (LEQEMBI) in the USA in January 2023 (later converted to a full approval in July 2023) marked the second anti-amyloid beta therapy approved for the disease. Lecanemab, a monoclonal antibody that targets the N3pG amyloid beta peptide which plays an important role in the formation of amyloid plaques in the brain, is indicated for treating early-stage Alzheimer's.
Despite the withdrawal from the market of aducanumab, the Alzheimer's disease market is entering a phase of growth with the US FDA approval in July 2024 of Lilly's donanemab (KISUNLA), an anti-N3pG amyloid beta peptide monoclonal antibody, for the treatment of adults with early symptomatic Alzheimer's disease. Donanemab provides a second treatment option for patients in the early stages of Alzheimer's disease and is expected to challenge lecanemab in a market square-off. Donanemab and may hold several advantages: it is administered as an intravenous infusion once monthly compared with lecanemab which is dosed biweekly offering a convenience edge but more significant is that donanemab can be stopped once patients amyloid levels have been successfully reduced, enabling fewer infusions and lower treatment costs.
Download the full article to learn more about the treatment options for Alzheimer's disease, R&D challenges of Alzheimer's therapeutic innovation, Next-generation therapies for Alzheimer's disease, future directions and more.
Alzheimer's manifests mainly in individuals aged 65 years and older and is the most common form of dementia. The disease progresses in three stages: the preclinical stage without symptoms; the prodromal stage with mild cognitive impairment and the dementia stage with functional impairment.1 The World Health Organization has estimated that Alzheimer's and other dementias affect more than 55 million people worldwide and impose a global annual economic burden of USD 1.3 trillion in associated healthcare costs.
Treatment options for Alzheimer's disease
There are currently no drugs that cure, prevent or reverse the course of Alzheimer's disease and available treatments provide symptomatic relief of symptoms such as memory loss for a limited time. The two main classes of therapeutics include cholinesterase inhibitors, which prevent the breakdown of the neurotransmitter acetylcholine, and N-methylD-aspartate receptor antagonists that regulate the activity of glutamate excitotoxiity.
Biogen won the race to get the first of a new category of medication to market for Alzheimer's disease with the accelerated approval of aducanumab (ADUHELM), a humanized monoclonal antibody that targets amyloid beta, in the USA in June 2021. However, many healthcare providers and insurers have refused to cover aducanumab due to a lack of clear clinical benefit. In January 2024, Biogen announced it will discontinue the development and commercialization of aducanumab to reprioritize resources to advance new treatment modalities in this therapeutic area. Patients who are receiving aducanumab as part of a clinical trial and by prescription will have access to the drug until May 2024 and Nov 2024, respectively.
The accelerated approval of Eisai and Biogen's lecanemab (LEQEMBI) in the USA in January 2023 (later converted to a full approval in July 2023) marked the second anti-amyloid beta therapy approved for the disease. Lecanemab, a monoclonal antibody that targets the N3pG amyloid beta peptide which plays an important role in the formation of amyloid plaques in the brain, is indicated for treating early-stage Alzheimer's.
Despite the withdrawal from the market of aducanumab, the Alzheimer's disease market is entering a phase of growth with the US FDA approval in July 2024 of Lilly's donanemab (KISUNLA), an anti-N3pG amyloid beta peptide monoclonal antibody, for the treatment of adults with early symptomatic Alzheimer's disease. Donanemab provides a second treatment option for patients in the early stages of Alzheimer's disease and is expected to challenge lecanemab in a market square-off. Donanemab and may hold several advantages: it is administered as an intravenous infusion once monthly compared with lecanemab which is dosed biweekly offering a convenience edge but more significant is that donanemab can be stopped once patients amyloid levels have been successfully reduced, enabling fewer infusions and lower treatment costs.
Download the full article to learn more about the treatment options for Alzheimer's disease, R&D challenges of Alzheimer's therapeutic innovation, Next-generation therapies for Alzheimer's disease, future directions and more.
Related solutions
Analytics Link Ecosystem
IQVIA Analytics Link Ecosystem establishes deep connections across our key data assets.